Dama Health’s Post

𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐫𝐞𝐚𝐝 𝐒𝐈𝐄 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐅𝐞𝐦𝐭𝐞𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭? 28 pages later and here are some key points that jumped out to me! 🌟 The Femtech sector as a whole, is projected to be worth over $𝟔𝟎𝐁𝐧 by 2027. 🌟 Leading regions in Europe for Femtech include the UK (31.8%), France (18.3%), Germany (12%), Sweden (7.9%) and Switzerland (5.5%). 🌟 Female founded Femtech start-ups raised $4.6M compared to $9.2M by those with all-male teams on average. 🌟 Investment in Women's Health has grown with deal counts up by 314% since 2018. 🌟 𝐎𝐧𝐥𝐲 𝟒% of all healthcare R&D is targeted at Women's Health issues specifically (🙄 *big sigh*). 🌟 Investing $300 million in women's health research = $𝟏𝟑 𝐁𝐈𝐋𝐋𝐈𝐎𝐍 for the US economy in the next 13-25 years. 🌟 𝐎𝐧𝐥𝐲 𝟏𝟓% of EU VC General Partners are women!! Worth a read to all my Femtech connections! If you have read it, what was most interesting to you? #femtech #vcfunding #sieventures Read the whole report here: https://lnkd.in/e4diNmEJ

#ICYMI: MedTech Strategist/Market Pathways's own Stephen Levin will be moderating the "Successfully Navigating Exits and Financings in Tough Times" panel discussion between Earlybird Venture Capital's Dr. Christoph Massner and LimFlow SA's Dan Rose at MedTech Europe's The MedTech Forum 2024 on Thursday, May 23 at 10:40AM-11:30AM. Despite a challenging environment for M&A and fundraising amidst an evolving EU regulatory landscape, this panel features strategics, investors and start-up CEOs who are doing deals in spite of these obstacles, and are here to share their strategies in achieving these goals. Lean more here: https://lnkd.in/ex3Y9ySx #MTF2024 #conferences #paneldiscussion #medtech #medtechindustry #medtechinnovation #regulatory

📣 Keeping The Cash Flow - Sustaining Momentum Through Maturation Join our panel of #MedtechLeaders as they discuss: ·  What trends or strategies do investors prioritize when assessing a medtech company's revenue outlook ·  How do successful medtech firms attract later-stage funding amid challenging economic conditions ·  Key considerations for medtech firms utilizing venture debt as a catalyst for sustained growth 🎙 Hear from: ·  David Kereiakes, Managing Partner, Windham Venture Partners ·  Darshana Zaveri, Managing Partner, Catalyst Health Ventures ·  Karthik Bolisetty, Senior Associate, Gilde Healthcare Find out more: https://lnkd.in/ey4UQiAP #LSXWorld 

❔ What are the barriers hindering consideration of this burgeoning sector? ❔ How can we attract new and larger investors? These are just a couple of questions that Maria De Santis, Muse Capital, Abbie Strabala, True Wealth Ventures, Rachel Braun Scherl, SPARK Solutions for Growth and Sriya Srinath, Morgan Health will answer in our next panel "Unlocking Potential: Perspectives from Prominent Investors in Femtech and Consumer Health". From understanding market trends to addressing regulatory concerns and fostering innovation, our panellists will offer strategic perspectives on unlocking investment opportunities in Femtech and consumer health. #FCIS #Femtech #Innovation #WomensHealth

Geoff Meyerson of Locust Walk, shared insights with Chief Medical Officer 360º on 2024 fundraising and business development trends. Discover how CMOs can enhance investor interactions. Don't miss advice for biotechs & CMOs navigating financing complexities.    Read the full article for a comprehensive overview and strategic outlook: https://lnkd.in/eMWjGXU8    #BiotechTrends #FinancialOutlook #CMOStrategies #InvestorRelations 

Revisiting an outstanding 2023, #LSIAlumni raised more than $1.67 Billion in capital and closed 11 M&A transactions across 117+ total deals. Our new spreadsheet indexes these transactions, investors involved (publicly disclosed), and links to our proprietary media and coverage of the companies themselves. 🔗 Click here to see the 2023 LSI Alumni Funding Report: https://lnkd.in/gzSb_tKX We’ve received great feedback on this report from founders, VCs, strategics, and many other executives in Medtech and Healthtech, and look forward to publishing more resources on the news and stories of our growing global community. You’ll also see many of the alumni featured on this report at #LSIUSA24 this March. We’re less than 7 weeks away and have selected over 300 of the most exciting emerging companies in the industry to present to a full house of investors and strategics. Click the link above to see 117+ LSI Alumni deals from 2023.

⭐ With PitchBook's recent Q1 2024 Medtech report being released there are promising signs for the medtech industry. 📈 Medtech VC funding is up $500 million from $2.8 billion to $3.3 billion quarter-over-quarter. ⏳ Deals are slowing with lower deal counts (down 15.7% on last quarter) - potentially due to the upcoming US election engendering caution among investors. 💸 Average deal value is up 20.1% over 2023 Q4. Are investors taking a quality over quantity approach? ❓ Private Equity remain cautious among high costs of debt - only 5 PE growth deals were executed, though there were 14 PE buyouts in the medtech sector. #medtech #medtechinvesting #medicaldevices #mergersandacquisitions #investment https://lnkd.in/eu7ZkNDQ

Excited to share that I will be one of only 4 companies presenting at the Keiretsu Forum SoCal Accredited Investor Event today. Keiretsu is the world's largest invitation-only angel investor network with over 3,000 accredited members throughout 64 chapters. Today's event is a regional one with four chapters in attendance. After our successful presentation at the Global Capital Network investor conference last month, Keiretsu approached us. Following two interviews, we are now accepted into the Keiretsu Forum. Impressively, several board members had heard us speak at the same event a year ago and were impressed by our growth and advancements at Oxygen4Life! Join me for my Zoom presentation today from 10AM - NOON where I will be presenting shortly after 11AM. Comment below "link" to get the registration link. You can also request the replay by commenting "link." A big thank you to my entire team and all supporters for helping shape Oxygen4Life. Thank you to my son Alexander Maunu, who without his help, support and putting up with me none of this would have been possible. I love you son! As we prepare for growth and scaling, our focus is on providing technology and solutions for early diagnosis of chronic inflammatory diseases and pain management without drugs or invasive procedures involving radiation. With FDA Cleared Medical Devices, AI-driven non-invasive testing devices, evidence-based patented supplements, and a commitment to sustainability, we offer personalized solutions for managing chronic pain and inflammatory diseases. Our approach aims at improving quality of life and long-term health benefits. #medtech #biotech #wellness #oxygen4life #keiretsu #letsdothis

While the typical MedTech company raises less than $50 million, achieving multi-billion dollar exits often demands much more. It’s crucial to look beyond traditional VC, tapping into wealthier families and family offices globally. My goal is to showcase this through my show, highlighting that while returns might not mirror those in software, investing in MedTech means contributing to social good and advancing humanity. State of MedTech #medtech

After a productive networking break in the Great Room Foyer, we now have the “Medtech by the Numbers” Panel Session, moderated by Jennifer McMahon, Partner at Seroba.: • Inga D. Deakin, Principal, Molten Ventures • Megan MacDonagh, Vice President, SV Health Investors • Anne Portwich, Partner, EQT Life Sciences  • Sylvain Sachot, Partner, Asabys Partners 2023 life science investment went down across the board, in biotech and medtech equally, but in diagnostics and healthtech to a greater degree. A panel of European VCs discusses what’s in store for 2024. The number of up-rounds is down, which is a negative for VC firms supporting early-stage companies. The situation needs to change in order to reward early investment, the lifeblood of medtech innovation. We are seeing a lot of structured deals, option deals with many milestones. It does look good when a strategic is interested in a company, and it provides a path for exit. But it is a two-sided sword.   Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI